Bullfrog AI (BFRG) Competitors $1.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.25 -0.02 (-1.18%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRG vs. PRLD, ALGS, IPSC, VTVT, CVM, OSTX, KLRS, XCUR, ATHE, and STTKShould you be buying Bullfrog AI stock or one of its competitors? The main competitors of Bullfrog AI include Prelude Therapeutics (PRLD), Aligos Therapeutics (ALGS), Century Therapeutics (IPSC), vTv Therapeutics (VTVT), CEL-SCI (CVM), OS Therapies (OSTX), Kalaris Therapeutics (KLRS), Exicure (XCUR), Alterity Therapeutics (ATHE), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Bullfrog AI vs. Its Competitors Prelude Therapeutics Aligos Therapeutics Century Therapeutics vTv Therapeutics CEL-SCI OS Therapies Kalaris Therapeutics Exicure Alterity Therapeutics Shattuck Labs Bullfrog AI (NASDAQ:BFRG) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Which has more volatility and risk, BFRG or PRLD? Bullfrog AI has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BFRG or PRLD? 1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 33.9% of Bullfrog AI shares are owned by insiders. Comparatively, 63.9% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate BFRG or PRLD? Prelude Therapeutics has a consensus price target of $4.50, indicating a potential upside of 444.14%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer BFRG or PRLD? In the previous week, Prelude Therapeutics had 2 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for Prelude Therapeutics and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.00 equaled Prelude Therapeutics'average media sentiment score. Company Overall Sentiment Bullfrog AI Neutral Prelude Therapeutics Neutral Which has higher valuation and earnings, BFRG or PRLD? Bullfrog AI has higher earnings, but lower revenue than Prelude Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$60K199.39-$6.99M-$0.81-1.57Prelude Therapeutics$7M6.67-$127.17M-$1.69-0.49 Is BFRG or PRLD more profitable? Prelude Therapeutics' return on equity of -89.18% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -163.23% -139.94% Prelude Therapeutics N/A -89.18%-69.26% SummaryPrelude Therapeutics beats Bullfrog AI on 11 of the 14 factors compared between the two stocks. Get Bullfrog AI News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRG vs. The Competition Export to ExcelMetricBullfrog AIMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.96M$1.92B$5.45B$9.66BDividend YieldN/AN/A4.60%4.13%P/E Ratio-1.5733.5429.7824.63Price / Sales199.3948.94376.6279.71Price / CashN/A51.2424.8428.01Price / Book2.239.458.605.76Net Income-$6.99M-$62.35M$3.26B$266.93M7 Day Performance-2.31%-1.38%0.55%0.31%1 Month Performance-15.89%-3.91%1.41%0.14%1 Year Performance-50.78%21.61%36.52%22.83% Bullfrog AI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRGBullfrog AI0.9932 of 5 stars$1.27flatN/A-50.8%$11.96M$60K-1.574Upcoming EarningsPRLDPrelude Therapeutics2.7571 of 5 stars$0.85+0.9%$4.50+427.5%-83.2%$48.16M$7M-0.50120News CoverageGap UpALGSAligos Therapeutics4.2743 of 5 stars$7.86-1.8%$70.00+791.2%-44.1%$47.99M$3.94M-0.4590Earnings ReportIPSCCentury Therapeutics2.5627 of 5 stars$0.56-1.8%$4.20+656.8%-70.5%$47.91M$6.59M-1.92170Upcoming EarningsVTVTvTv Therapeutics2.443 of 5 stars$14.91+2.3%$35.50+138.2%+6.5%$47.65M$1.02M-4.969News CoverageUpcoming EarningsGap UpCVMCEL-SCI0.8947 of 5 stars$8.97-3.0%N/A-79.7%$47.62MN/A-18.6543Positive NewsGap DownOSTXOS Therapies2.4282 of 5 stars$1.70-2.0%$18.00+961.9%-59.0%$47.49MN/A-1.97N/AKLRSKalaris Therapeutics0.9982 of 5 stars$2.52-2.3%$3.00+19.0%N/A$47.12MN/A0.00110Gap DownXCURExicure0.9947 of 5 stars$7.62+0.3%N/A+1,305.4%$47.08M$500K-1.9550Earnings ReportUpcoming EarningsATHEAlterity Therapeutics1.5744 of 5 stars$5.28+1.3%$12.00+127.3%+332.0%$46.88MN/A0.0010STTKShattuck Labs2.988 of 5 stars$0.93+24.5%$7.50+710.8%-75.1%$46.27M$5.72M-0.69100Gap DownHigh Trading Volume Related Companies and Tools Related Companies Prelude Therapeutics Competitors Aligos Therapeutics Competitors Century Therapeutics Competitors vTv Therapeutics Competitors CEL-SCI Competitors OS Therapies Competitors Kalaris Therapeutics Competitors Exicure Competitors Alterity Therapeutics Competitors Shattuck Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRG) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bullfrog AI Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bullfrog AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access